The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments
Open accessAbstract
Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reported to be effective in various autoimmune diseases, including autoimmune bullous dermatoses. A specific protocol for the use of rituximab to treat BP patients is not yet available. There are only small case series and case reports about the efficacy and safety of rituximab in BP. Here we present a young BP patient who responded well to rituximab therapy and was refractory to conventional and omalizumab therapies although he had elevated IgE levels and eosinophilia. Our case supports the knowledge about the effectiveness and safety of rituximab not only in pemphigus but also in BP. On the other hand, although it did not work in our case, omalizumab may be a potentially effective agent in some carefully selected patients with certain subtypes of BP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody
Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., & Metzger, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912233412603 · Cited by 704
A Single Cycle of Rituximab for the Treatment of Severe Pemphigus
Joly, P., Mouquet, H., Roujeau, J.-C., D'Incan, M., Gilbert, D., Jacquot, S., Gougeon, M.-L., Bedane, C., Muller, R., Dreno, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067752 · Cited by 466
A review of the current use of rituximab in autoimmune diseases
Gürcan, H. M., Keskin, D. B., Stern, J. N. H., Nitzberg, M. A., Shekhani, H., & Ahmed, A. R. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.004 · Cited by 314
Fairley, J. A., Burnett, C. T., Fu, C.-L., Larson, D. L., Fleming, M. G., & Giudice, G. J. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700958 · Cited by 177
Omalizumab therapy for bullous pemphigoid
Yu, K. K., Crew, A. B., Messingham, K. A. N., Fairley, J. A., & Woodley, D. T. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.04.053 · Cited by 176
Messingham, K. N., Holahan, H. M., & Fairley, J. A. (2014) · Immunologic Research · doi:10.1007/s12026-014-8547-7 · Cited by 54
Cited by
Kasperkiewicz, M., Ellebrecht, C. T., Takahashi, H., Yamagami, J., Zillikens, D., Payne, A. S., & Amagai, M. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.26 · Cited by 523
New insights into the pathogenesis of asthma
Elias, J. A., Lee, C. G., Zheng, T., Ma, B., Homer, R. J., & Zhu, Z. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17748 · Cited by 407
Targeting B cells and plasma cells in autoimmune diseases
Hofmann, K., Clauder, A.-K., & Manz, R. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00835 · Cited by 294
Ben Mkaddem, S., Benhamou, M., & Monteiro, R. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00811 · Cited by 283
Regulation of Mast Cell Responses in Health and Disease
Gilfillan, A. M., & Beaven, M. A. (2011) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v31.i6.30 · Cited by 259
Metadata
- Authors
- Bilgiç Temel, A., Bassorgun, C. I., Akman-Karakaş, A., Alpsoy, E., & Uzun, S.
- Venue
- Case Reports in Dermatology
- Publisher
- S. Karger AG
- Published
- 2017-02-10
- Volume
- 9
- Issue
- 1
- Pages
- 38-44
- ISSN
- 1662-6567 (ISSN-L)
- OpenAlex
- W2588368793
- Cited by
- 363
- References
- 6
- FWCI
- 23.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments. https://app.cochat.ai/papers/10.1159/000452828
- The paper
- Bilgiç Temel, A., Bassorgun, C. I., Akman-Karakaş, A., Alpsoy, E., & Uzun, S. (2017). Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments. Case Reports in Dermatology. https://doi.org/10.1159/000452828
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
